Literature DB >> 20463634

Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.

Lewis Couchman1, Phillip Edgar Morgan, Edgar Pathrose Spencer, Robert James Flanagan.   

Abstract

Therapeutic drug monitoring of plasma clozapine and of its principal plasma metabolite N-desmethylclozapine (norclozapine) (predose or "trough" sample) can help in monitoring adherence, in dose adjustment, and in minimizing the risk of toxicity. To obtain data to assist in the interpretation of analytical results, the results from a clozapine therapeutic drug monitoring service, 1993-2007, have been audited. There were 104,127 samples from 26,796 patients [18,750 (70%) men aged at time of first sample (median, range) 34 (10-89) years, and 7763 (30%) female aged 38 (12-90) years]. Clozapine was not detected (plasma concentration <0.01 mg/L) in 1.5% of samples (prescribed clozapine dose up to 900 mg/d). Plasma clozapine was either below 0.35 mg/L or greater than 0.60 mg/L in 42.5% and 28.4% of samples, respectively; in 0.4% samples plasma clozapine was 2.0 mg/L or more. Although plasma clozapine was broadly related to prescribed dose, there was much variation: 1.2% of samples had plasma clozapine >1.0 mg/L at prescribed clozapine doses up to 150 mg/d (76.2% < 0.35 mg/L), whereas 23.3% of samples had plasma clozapine < 0.35 mg/L at doses of 850 mg/d and over (18.0% > 1.0 mg/L). The highest plasma clozapine and norclozapine concentrations encountered were 4.95 and 2.45 mg/L, respectively. Although the median plasma clozapine:norclozapine ratio was 1.25 at plasma clozapine concentrations < 0.35 mg/L, the median ratio was 2.08 at plasma clozapine concentrations > 1.0 mg/L. Data (median, 10th-90th percentile) for both clozapine and norclozapine by prescribed clozapine dose band are useful in assessing partial adherence. Analysis of the plasma clozapine:norclozapine ratio by clozapine concentration provides clear evidence that clozapine N-demethylation becomes saturated at higher plasma clozapine concentrations and adds urgency to the requirement for dose adjustment should smoking habit change. A clozapine:norclozapine ratio greater then 2 suggests either a nontrough sample, or that clozapine N-demethylation has become saturated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463634     DOI: 10.1097/FTD.0b013e3181dad1fb

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  31 in total

1.  Interaction between clozapine and oxcarbazepine: a case report.

Authors:  Hazel Yousra; Lebain Pierrick; Lecardeur Laurent; Debruyne Danièle
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-15

2.  A Reasonable Alternative to Clozapine in the Chronically Relapsing Smoking Patient? A Retrospective Analysis.

Authors:  John R Tomko; Nadeem Ahmed; Cynthia Kuntz; Justine Zick
Journal:  Hosp Pharm       Date:  2016-11

3.  Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.

Authors:  Li-jun Li; De-wei Shang; Wen-biao Li; Wei Guo; Xi-pei Wang; Yu-peng Ren; An-ning Li; Pei-xin Fu; Shuang-min Ji; Wei Lu; Chuan-yue Wang
Journal:  Acta Pharmacol Sin       Date:  2012-07-23       Impact factor: 6.150

4.  Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders.

Authors:  Ulrich C Lutz; Ahmad Sirfy; Gerlinde Wiatr; Danuta Altpass; Gisbert Farger; Thomas Gasser; Kathrin N Karle; Anil Batra
Journal:  Eur J Clin Pharmacol       Date:  2014-10-18       Impact factor: 2.953

5.  Fusing Sensor Paradigms to Acquire Chemical Information: An Integrative Role for Smart Biopolymeric Hydrogels.

Authors:  Eunkyoung Kim; Yi Liu; Hadar Ben-Yoav; Thomas E Winkler; Kun Yan; Xiaowen Shi; Jana Shen; Deanna L Kelly; Reza Ghodssi; William E Bentley; Gregory F Payne
Journal:  Adv Healthc Mater       Date:  2016-09-12       Impact factor: 9.933

6.  Genetic Determinants of Clozapine-Induced Metabolic Side Effects.

Authors:  Kamini Vasudev; Yun-Hee Choi; Ross Norman; Richard B Kim; Ute I Schwarz
Journal:  Can J Psychiatry       Date:  2016-09-29       Impact factor: 4.356

7.  Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice.

Authors:  Christopher Wohkittel; Manfred Gerlach; Regina Taurines; Christoph Wewetzer; Stefan Unterecker; Rainer Burger; Diana Schreck; Claudia Mehler-Wex; Marcel Romanos; Karin Egberts
Journal:  J Neural Transm (Vienna)       Date:  2016-05-24       Impact factor: 3.575

Review 8.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

9.  Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.

Authors:  Kathryn K Erickson-Ridout; Dongxiao Sun; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

Review 10.  [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].

Authors:  H Javelot; P-M Llorca; D Drapier; E Fakra; C Hingray; G Meyer; S Dizet; A Egron; C Straczek; M Roser; M Masson; R Gaillard; P Fossati; E Haffen
Journal:  Encephale       Date:  2020-05-04       Impact factor: 1.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.